NEWTON, Mass., June 3 /PRNewswire-FirstCall/ -- Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation (OTC Bulletin Board: MFLU), and POWREX Corporation have entered into an exclusive distributorship agreement whereby POWREX will market, sell and service Microfluidizer(R) high shear fluid processors in the pharmaceutical, biotechnology and energy industries throughout Japan.
Japan is the second-largest individual country pharmaceutical market in the world, and is a clear leader in innovative energy technologies, including fuel cells and photovoltaics. With this agreement, POWREX customers throughout Japan will be able to take wider advantage of the unique benefits provided by Microfluidizer high shear fluid processors to improve quality and efficiency in the lab as well as production.
POWREX will distribute the entire line of Microfluidizer top-down processors, which represents the widest range of pharmaceutical processors available, as well as novel Microfluidics Reaction Technology (MRT) for bottom-up creation of nanoparticles and efficient nanoencapsulation via continuous crystallization and chemical reactions.
"Microfluidics is honored to partner with such a respected corporation as POWREX," said Michael C. Ferrara, Microfluidics Chief Executive Officer. "We believe Microfluidizer processors are the undisputed gold standard in the biopharma industry, and MRT represents a tremendous opportunity particularly for energy researchers. We believe POWREX is well positioned to bring these technologies to a market eager for solutions."
Established in 1950 as Fuji Kikai Kohgyo Co, Ltd., and based in Hyogo, POWREX has grown over the past half-century to become one of the largest processing technologies companies in Japan. POWREX partners with its customers to deliver value-added original powder processing solutions including hardware, software and engineering services. By supplementing these core offerings with Microfluidics technology, POWREX will provide a more complete suite of best-in-class processors and scientific expertise to support customers' demanding research requirements.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these statements by the fact that they use words such as "anticipate," "believe," "estimate," "expect," "intend," "project," "plan," "outlook," and other words and terms of similar meaning. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Among the factors that could cause actual results and outcomes to differ materially from those contained in such forward-looking statements are the following: our ability to access sufficient working capital, including a new working capital line; our continued compliance with the representations, warranties and covenants under our existing convertible debenture; our continued history of losses, which includes net losses in three of the last five fiscal years; the timing and size of customer orders for our products; the adoption, timing and performance of new technology and products developed by us; changes and advances in technology that may make our products obsolete or reduce demand for our products; our ability to protect and maintain the confidentiality of our intellectual property; our ability to retain key employees and our reliance on a new management team; changes in governmental rules and regulations, including those regulating the exportation of goods; and general economic and business conditions and the financial crisis, including those adversely effecting the pharmaceutical and biotechnology industries. For a more detailed discussion of risks and uncertainties which could cause actual results to differ from those contained in our forward-looking statements, see Item 1A, "Risk Factors" of our most recently filed Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and our other periodic reports filed with the SEC. You should not place undue reliance on our forward-looking statements, which speak only as of the date they are made. We are providing this information as of this date, and we do not undertake to update the information included in this press release, whether as a result of new information, future events or otherwise.
Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. Microfluidics is a leader in innovative technology and comprehensive solutions for formulations requiring repeatability and for the production of uniformly distributed nanoparticles.
Microfluidics has been a worldwide supplier of Microfluidizer(R) high shear fluid processing systems to the biotechnology, pharmaceutical, chemical and cosmetics industries since 1984. As a leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.
Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at any of three Microfluidics facilities. Visit www.microfluidicscorp.com, email firstname.lastname@example.org or contact Microfluidics at 800.370.5452 for application information.
|SOURCE Microfluidics International Corporation|
Copyright©2009 PR Newswire.
All rights reserved